Pharmacology of therapeutic antibodies



Authors: Theodora Bejan-Angoulvant (1,2,3), François Darrouzain (1), Céline Desvignes (2,3), Olivier Le Tilly (1,2,3), Marc Ohresser (3), Gilles Paintaud (1,2,3), David Ternant (1,2,3) and Nicolas Azzopardi (4)


(1) Department of Medical Pharmacology and (2) CePiBAc, Tours University Hospital, and (3) EA 4245 T2I research unit, (4) UMR Physiologie de la Reproduction et des Comportements, Tours-Nouzilly, France

Update: Septembre 28th, 2023


Lobet S, Caulet M, Paintaud G, Azzopardi N, Desvignes C, Chautard R, Borg C, Capitain O, Ferru A, Bouché O, Lecomte T, Ternant D.

Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients. Br J Clin Pharmacol, accepted.


Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, Soubrier M, Avouac J, Brocq O, Sellam J, de Vries N, Huizinga TWJ, Jury EC, Manson JJ, Mauri C, Matucci A, Hacein Bey Abina S, Mulleman D, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. 

Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw Open 2023, 6(7):e2323098.

Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D.

Randomized phase III trial evaluating subcutaneous rituximab for the first-line treatment of low-tumor burden follicular lymphoma: results of a LYSA study. J Clin Oncol 2023, 41(19):3523-3533. 

de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, le Bourgeois A, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, Guyen SN, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Sanchez VP, Tardivon C, Blancho G, Lévy V.

Low serum neutralization of Omicron variants a month after AZD7442 [tixagevimab/cilgavimab, Evusheld®] prophylaxis initiation. J Infect 2023, 86(1):66-117.

Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Pivot C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T.

Efficacy and safety of bevacizumab on severe bleedings associated with hereditary hemorrhagic telangiectasia. A national, randomized multicenter phase III trial. J Intern Med 2023, 294 (6) : 761-774.

Le Tilly O, Ternant D, Bejan-Angouvant T, Paintaud G.

[Pharmacokinetics of monoclonal antibodies] - Pharmacocinétique des anticorps monoclonaux. La Lettre du Pharmacologue N° 2 (juin 2023)

Lobet S, Paintaud G, Azzopardi N, Passot C, Caulet M, Chautard R, Desvignes C, Capitain O, Tougeron D, Lecomte T, Ternant D

Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 2023, 62(9):1263-1274.

Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Gomez E, Gondouin A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Leger J, Kerjouan M, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Bejan-Angoulvant T, Cottin V, Marchand-Adam S ; EVER-ILD investigators and the OrphaLung network.

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023, 61(6):2202071.

Pasquiers B, Benamara S, Felices M, Ternant D, Declèves X, Puszkiel A.

Translation of monoclonal antibodies pharmacokinetics from animal to human using physiologically based modeling in open systems pharmacology (OSP) suite: A retrospective analysis of bevacizumab. Pharmaceutics 2023, 14;15(8)

Ternant D, Le Tilly O, Bejan-Angoulvant T, Paintaud G.

[Pharmacology of monoclonal antibodies in asthma] - Pharmacologie des anticorps monoclonaux dans l’asthme sévère (modélisation PK et PK-PD). La Lettre du Pharmacologue N° 2 (juin 2023).

Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, N'Guyen S, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Barthélémy K, Priet S, Nurtop E, Sanchez VP, Tardivon C, Blancho G, Le Bourgeois A, Lévy V. 

Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 [tixagevimab/cilgavimab, Evusheld®] 600 mg. J Infect 2023, 86(5):e126-e129.


Azzopardi N, Longuet H, Ternant D, Thibault G, Gouilleux-Gruart V, Lebranchu Y, Büchler M, Gatault P, Paintaud G

Relationship between antithymocyte globulin concentrations and lymphocyte sub-populations in kidney transplant patients. Clin Pharmacokinet 2022, 61(1):111-122

Bensalem A, Cartron G, Specks U, Mulleman D, Gyan E, Cornec D, Desvignes C, Casasnovas O, Lamy T, Leprêtre S, Paintaud G, Ternant D.

The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition. Clin Pharmacokinet 2022, 61(3):423-437.

Le Tilly O, Gatault P, Baron C, Bejan-Angoulvant T, Büchler M, Paintaud G, Ternant D.

Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition (TMDD) model. Br J Clin Pharmacol 2022, 88(7):3500-3505.

Randrian V, Pernot S, Le Malicot K, Catena V, Baumgaertner I, Tacher V, Forestier J, Hautefeuille V, Tabouret-Viaud C, Gagnaire A, Mitry E, Guiu B, Aparicio T, Smith D, Dhomps A, Tasu JP, Perdrisot R, Edeline J, Capron C, Cheze-Le Rest C, Emile JF, Laurent-Puig P, Bejan-Angoulvant T, Sokol H, Lepage C, Taieb J, Tougeron D. 

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, bevacizumab and atezolizumab in liver-dominant metastatic colorectal cancer. Dig Liver Dis 2022, 54(7):857-863.

Ternant D, Pfister M, Le Tilly O, Mulleman D, Picon L, Willot S, Passot C, Bejan-Angoulvant T, Lecomte T, Paintaud G, Koch G.

Infliximab treatment does not lead to full TNF-α inhibition: a target-mediated drug disposition model. Clin Pharmacokinet 2022, 61(1):143-154




Campone C, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, Arnedos M, Loussouarn D, Wang Q, Vanlemmens L, Jimenez M, Rios M, Diéras V, Leroux A, Paintaud G, Rezai K, André F, Lion M, Merlin JL.

A phase II randomized study of preoperative trastuzumab alone or combined to everolimus in early HER2-positive breast cancer patients and predictive biomarkers (RADHER trial). Eur J Cancer 2021, 158 : 169-180 (free access)

Chautard R, Corset L, Ibrahim S, Paintaud G, Baroukh N, Guéguinou M, Lecomte T, Raoul W.

Anti-EGFR monoclonal antibodies panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells. Biomark Med 2021, 15(10):685-696.


Desvignes C, Ternant D, Lecomte T, Lièvre A, Ohresser M, Chautard R, Raoul W, Paintaud G.

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. Bioanalysis 2021, 13(7):565-574.


Gagez AL, Paul F, Alaterre E, Gouilleux-Gruart V, Tuaillon E, Lepretre S, Ternant D, Letestu R, Moreaux J, Cartron G. 

Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study [rituximab]. Leuk Lymphoma 2021, 62(13):3160-3169

Kokkali S, Ternant D, Kemmel V, Levêque D, Wendling F, Barthelemy P, Kurtz JE.

Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis. Br J Clin Pharmacol 2021, 87(8):3372-3374 (free access)

Law-Wan J, Sparfel MA, Derolez S, Azzopardi N, Goupille P, Detert J, Mulleman D, Bejan-Angoulvant T. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open 2021 Nov;7(3):e001882.


Le Tilly O, Azzopardi N, Bonneau C, Desvignes C, Ezzalfani M, Ternant D, Turbiez I, Gutierrez M, Paintaud G.

Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration. Clin Pharmacol Ther 2021, 110(1):210-219

Le Tilly O, Paintaud G, Ternant D

Therapeutic drug monitoring vs standard therapy during infliximab induction in patients with chronic immune-mediated inflammatory diseases (letter). JAMA 2021, 326(11):1069. 


Le Tilly O, Bejan-Angoulvant T, Paintaud G, Ternant D.

Letter to Dreesen et al. on their article “Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease”. Br J Clin Pharmacol 2021, 87(3):1594-1595

Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, Ternant D, Lacarelle B, Guitton J, Ciccolini J, Blanchet B.

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals (Basel) 2021, 14(8):796


Mayor A, Chesnay A, Desoubeaux G, Ternant D, Heuzé-Vourc'h N, Sécher T.

Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives. Vaccines (Basel) 2021, 9(2):151. (free access)


Ngo-Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, Bejan-Angoulvant T.

Cardiovascular adverse events with intravitreal anti-Vascular Endothelial Growth Factor drugs: A meta-analysis of randomized controlled trials. JAMA Ophtalmol 2021, 139(6):1-11


Ngo Ntjam N, Angoulvant D, Bejan-Angoulvant T.

Association between mortality and anti-Vascular Endothelial Growth Factor treatment in patients with age-related macular degeneration (reply). JAMA Ophthalmol 2021, 139(11):1247-1248.

Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P.

Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study. Br J Clin Pharmacol 2021, 87(5):2236-2246


Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Desvignes C, Navarro-Teulon I, Mouret-Reynier MA, Coudert B, Paintaud G

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early breast cancer. Eur J Clin Pharmacol 2021, 77(12):1861-1873.


Ternant D, Le Tilly O, Picon L, Moussata D, Passot C, Bejan-Angoulvant T, Desvignes C, Mulleman D, Goupille P, Paintaud G.

Infliximab efficacy may be linked to full TNF-α blockade in peripheral compartment - a double central-peripheral Target-Mediated Drug Disposition (TMDD) Model. Pharmaceutics 2021, 13(11):1821 (free access)

Thibault G, Paintaud G, Cheng Sung HC, Lajoie L, Louis E, the GETAID, Desvignes C, Watier H, Gouilleux-Gruart V, Ternant D.

Platelets and FcγRIIA: two pieces to the puzzle of human IgG clearance. Int J Mol Sci 2021, 22:6051 (free access)




Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, Cadranel J, Crestani B, Cottin V, Marchand-Adam S; OrphaLung.

Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial. Respir Med Res 2020, 78:100770. (free access)


Bensalem A, Ternant D.

Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet 2020, 59(7):857-874


Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Cheu M, Snyder MR, Hummel AM, Gouilleux-Gruart V, Cornec D, Specks U, Ternant D.

Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis. Clin Pharmacokinet 2020, 59(4):519-530


Coudert B Pierga PY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Le Du F, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L.

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised AVATAXHER study. EClinicalMedicine 2020, 28,100566,1-9. (free access)


Dolly A, Lecomte T, Bouché O, Borg C, Terrebonne E, Douillard JY, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas JF, Servais S, Baracos VE.

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. Clin Nutr 2020, 39(11):3319-3330. (free access)


Ducourau E, Rispens T, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Solau-Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D.

Methotrexate reduces adalimumab immunogenicity in patients with axial spondyloarthritis: a multicentric randomized trial. RMD Open 2020, 6(1)pii:e001047. (free access)


Petitcollin A, Bensalem A, Verdier M-C, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D.

Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet 2020, 59(1):37-49


Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godeth J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC.

Skin inflammatory response and efficacy of anti-Epidermal Growth Factor Receptor in metastatic colorectal cancer (CUTACETUX). Oncoimmunology 2020, 9(1):1848058




Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghea M, Berthou C, Paintaud G, Renaudineau Y.

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer 2019, 7(1):22. 

Bejan-Angoulvant T, Alexandre J.

[Mechanism of action and adverse effects of monoclonal antibodies]. (French) Med Sci (Paris) 2019, 35(12):1114-1120. 


Bensalem A, Mulleman D, Thibault G, Azzopardi N, Goupille P, Paintaud G, Ternant D.

CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol 2019, 85(12):2747-2758. 


Lioger B, Maillot F, Ternant D, Passot C, Paintaud G, Bejan-Angoulvant T.

Efficacy and safety of the anti-D immunoglobulins versus intravenous immunoglobulins for immune thrombocytopenia in children: systematic review and meta-analysis of randomized controlled trials. J Pediatr 2019, 204:225-233.


Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegrin A, Poul MA.

A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs 2019, 11(3):593-605.


Nemoz B, Ternant D, Bailly S, Gautier-Veyret E, Jourdil JF, Bonaz B, Stanke-Labesque F.

New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2019, 85(4):722-728.


Nguyen TT, Angeli E, Darrouzain F, Nguyen QT, Desvignes C, Rigal M, Nevine O, Nicolas P, Le QV, Winterman S, Pailler MC, Zelek L, Paintaud G, Janin A, Bousquet G.

A successful compartmental approach for the treatment of breast cancer brain metastases [trastuzumab]. Cancer Chemother Pharmacol 2019, 83(3):573-580.


Sécher T, Dalonneau E, Ferreira M, Parent C, Azzopardi N, Paintaud G, Si-Tahar M, Heuzé‑Vourc’h N.

In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration [anti-P. aeruginosa mAb]. J Control Release 2019, 303:24-33. 


Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G.

Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet 2019, 58(2):169-187. 


Ternant D, Monjanel H, Venel Y, Prunier-Aesch C, Arbion F, Colombat P, Paintaud G, Gyan E.

Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study. Br J Clin Pharmacol 2019, 85(9):2002-2010. 


Ternant D, Chhun S.

[Pharmacokinetic variability of therapeutic antibodies]. (French) Med Sci (Paris) 2019, 35(12):1130-1136. 




Bonneau C, Paintaud G, Dubot C, Desvignes C, Le rhun E, Trédan O, Dieras V, Taillibert S, Tresca P, Turbiez I, Lib J, Passot C, Mefti F, Fourme E, Gutierrez M.

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 2018, 95 : 75-84.


Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. Haematologica 2018, 103(8):e356-e359. 


Desvignes C, Passot C, Ternant D, Caulet M, Guérineau C, Lecomte T, Paintaud G.

Development and validation of an ELISA to study panitumumab pharmacokinetics. Bioanalysis 2018, 10 (4) : 205-214.


Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S.

Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol 2018, 13(4):509-515.


Hamdan D, Darrouzain D, Bejan-Angoulvant T, Isorni, Zelek L, Paintaud G, Janin A, Bousquet G.

A novel way to manage trastuzumab cardiotoxicity. Cancer Chemother Pharmacol 2018, 81 (4) : 791-796.


Ibrahim S, Raoul W, Lecomte T, Paintaud G, Ternant D.

Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. Eur J Cancer 2018, 92 : 119-120.


Ibrahim S, Girault A, Ohresser M, Lereclus E, Paintaud G, Lecomte T, Raoul W.

Monoclonal antibodies targeting IL-17/IL-17RA axis: an opportunity to fight metastatic colorectal cancer? Clin Colorectal Cancer 2018, 17 (1) : e109-e113. 


Petitcollin A, Leuret O, Tron C, Lemaitre F, Verdier MC, Paintaud G, Bouguen G, Willot S, Bellissant E, Ternant D.

Modelling immunization to infliximab in children with Crohn’s disease using population pharmacokinetics: a pilot study. Inflamm Bowel Dis 2018, 24 (8) : 1745-1754.


Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L, Lecomte T, Mulleman D, Paintaud G.

Model-based therapeutic drug monitoring of infliximab using a single serum trough concentration. Clin Pharmacokinet 2018, 57 (9) : 1173-1184. 


Thulliez M, Angoulvant D, Pisella PJ, Bejan-Angoulvant T.

Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti-Vascular Endothelial Growth Factor medication use. JAMA Ophthalmol 2018, 136(5):557-566.




Arnoult C, Brachet , Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, Paintaud G, Heuzé-Vourc’h N, Watier H, Gouilleux-Gruart V.

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice. J Immunol 2017, 199 (2): 418-424 


Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Mammou S, Paintaud G, Mulleman D.

Relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol 2017, 69 (1) : 108-113. 


Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, de Vries A.

Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients (review). Ther Drug Monit 2017, 39 (4) : 316-321.


Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ.

Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Ther Drug Monit 2017, 39(4):308-315.


Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W.

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer 2017, 17 (1) : 220. 


Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.

Pharmacokinetics of irinotecan, oxaliplatin and 5-fluorouracil during hepatic artery chronomodulated infusion: A translational European OPTILIV study [cetuximab]. Clin Pharmacokinet 2017, 56 (2) : 165-177. 


Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Mélet J, Paintaud G, Ternant D.

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 2017, 83 (8) : 1773-1781 


Medina F, Placensia C, Goupille P, Paintaud G, Balsa A, Mulleman D.

Therapeutic drug monitoring of biopharmaceuticals in spondyloarthritis (review). Ther Drug Monit 2017, 39 (4) : 360-363.


Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. Ther Drug Monit 2017, 39(4):364-369.


Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan Angoulvant T, Pascual-Salcedo D, Mulleman D.

Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases (review). Ther Drug Monit 2017, 39 (4) : 339-343.


Passot C, Pouw M, Mulleman D, Bejan-Angoulvant T, Paintaud G, Dreesen E, Ternant D.

Therapeutic drug monitoring of biologicals will benefit of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling (review). Ther Drug Monit 2017, 39 (4) : 322-326.


Passot C, Desvignes C, Ternant D, Bejan-Angoulvant T, Duveau AC, Gatault P, Paintaud G.

Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. Bioanalysis 2017, 9 (16) : 1227-1235.


Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Influence of FCGR3A-158V/F genotype and CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia. A study of FILO group. Clin Pharmacokinet 2017, 56 (6) : 635-647.


Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 2017, 129 (19) : 2616-2623.




Benhamou Y, Paintaud G, Azoulay E, Poullin P, Galicier L, Desvignes C, Baudel JL, Peltier J, Mira JP, Pène F, Presne C, Saheb S, Deligny C, Rousseau A, Féger F, Veyradier A, Coppo P ; French Reference Center for Thrombotic Microangiopathies.

Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study. Am J Hematol 2016, 91 (12) : 1246-1251. 


Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, Paintaud G, Ternant D.

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Br J Clin Pharmacol 2016, 81 (5) : 941-8. 


Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A.

Intrathecal trastuzumab halts progression of CNS metastases in breast cancer (research letter). J Clin Oncol 2016, 34 (16) : e151-5.


Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 2016, 55 (11) : 1381-1394.


Dannepond C, Ternant D, Maruani A, Machet L, Paintaud G, Samimi M.

Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis (research letter). Br J Dermatol 2016, 174 (1) : 198-200.


Passot P, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Paintaud G, Ternant D.

The underlying inflammatory chronic disease influences infliximab pharmacokinetics. Mabs 2016, 8 (7) : 1407-1416.


Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud G.

Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. Ther Drug Monit 2016, 38 (5) : 567-572.


Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS.

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). Eur J Clin Pharmacol 2016, 72 (2) : 253-5.


Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.

IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J Immunol 2016, 196 (2) : 607-13. 


Thibault G, Paintaud G, Legendre C, Merville P, Coulon M, Chasseuil E, Ternant D, Rostaing L, Durrbach A, Di Giambattista F, Büchler M, Lebranchu Y.

CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. Transpl Int 2016, 29 (2) : 184-95.


Tout M, Passot C, Cartron G, Paintaud G, Ternant D.

Letter to Gota et al. on their article "the pharmacokinetics of Reditux™, a biosimilar of rituximab". Cancer Chemother Pharmacol 2016, 78 (6) : 1317-1318.




Aubourg A, Picon L, Lecomte T, Bejan-Angoulvant T, Paintaud G, Ternant D.

A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease (research letter).

Eur J Clin Pharmacol 2015, 71 (12) : 1541-2.


Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G.

Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.

MAbs 2015, 7 (3) : 630-7.

Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M.

Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.

Acta Derm Venereol 2015, 95 (4) : 401-406.


Desvignes C, Edupuganti SR, Darrouzain F, Duveau AC, Loercher A, Paintaud G, Mulleman D.

Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration.

Bioanalysis 2015, 7 (10) : 1253-1260.


Edupuganti SR, Eder V, Ternant D, Courtehoux M, Tranquart F, Goupille P, Paintaud G, Mulleman D.

F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumour necrosis factor-α antagonist, in rheumatoid arthritis: a prospective pilot study.

Joint Bone Spine 2015, 82 (5) : 381-3.


Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H.

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

MAbs. 2015;7(6):1205-11. 


Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Pharmacogenomics 2015, 16 (18) : 2035-43.


Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, Holland MC, Erik P, Jensen H, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, Ross Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium.

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the innovative medicines initiative ABIRISK consortium.

Clin Exp Immunol 2015, 181 (3) : 385-400.


Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Le Loët X, Vittecoq O, Goupille P, Mulleman D, Paintaud G.

Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Br J Clin Pharmacol 2015, 79 (2) : 286-97. 


Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G.

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Clin Pharmacokinet 2015, 54 (5) : 551-62. 


Ternant D, Karmiris K, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, van Assche G, Paintaud G.

Pharmacokinetics of adalimumab in Crohn’s disease (research letter).

Eur J Clin Pharmacol 2015, 71 (9) : 1155-7.


Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G.

Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis (review).

Clin Pharmacokinet 2015, 54 (11) : 1107-23. 




Coudert B, Pierga PY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Lancet Oncol 2014, 15 (13) : 1493-1502.


Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.

Towards an individualized target concentration of adalimumab in rheumatoid arthritis (letter).

Ann Rheum Dis 2014, 73 (7) : 1428-1429.


Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F.

ELLIPSE Study: A phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in Hereditary Hemorrhagic Telangiectasia.

MAbs 2014, 6 (3) : 793-798.


Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andrès C, Hérault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc’h N.

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.

J Control Release 2014, 196 : 344-354


Hervé V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenet D, Joubert JM, Gottenberg JE, Paintaud G and participants of round table N°2 of Giens XXIX: Augendre-Ferrante B, Cans C, Cellier D, Chevalier MP, Diaz I, Filipecki J, Kahn JE, Le Men J, Mulleman D, Urbain R, Vasmant D.

Translational Research in Immune and Inflammatory Diseases; What are the Challenges, Expected Advances, and Innovative Therapies?

Therapie 2014, 69 (4) : 297-302. 

Montharu J, Redini F, Paintaud G, Lemarié E, Cadranel J, Wislez M, Heuzé-Vourc'h N.

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.

MAbs 2014, 6 (6) : 1638-1648.


Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H.

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Cancer Chemother Pharmacol 2014, 73 (6) : 1303-1306.


Le Moigno L, Ternant D, Paintaud G, Thibault G, Cloarec S, Tardieu M, Lagrue E, Castelnau P.

Encéphalite à anticorps anti-récepteurs N-méthyl-D-aspartate (NMDA-R) : place des immunomodulateurs.

Arch Pediatr 2014, 21 (6) : 620-623.


Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D,

Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M,

Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P.

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.

Inflamm Bowel Dis 2014, 20 (6) : 978-986.


Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G.

Influence of FcgRIIIA genetic polymorphism on lymphocyte depletion induced by rabbit antithymocyte globulins (r-ALG) in kidney transplant patients.

Pharmacogenet Genomics 2014, 24 (1) : 26-34.


Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau‑Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D.

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.

Br J Clin Pharmacol 2014, 78 (1) : 118-128.


Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan‑Angoulvant T.

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

JAMA Ophthalmol 2014, 132(11):1317-26.



Azzopardi N, François M, Laurent E, Paintaud G, Birmelé B.

Influence of plasma exchange on rituximab pharmacokinetics (letter).

Br J Clin Pharmacol 2013, 76 (6) : 486-488.

Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, Ternant D, Foulon C, Pilorge B, Lemay D, Sung C, Halimi JM, Baron C, Lebranchu Y.

Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial.

Transpl Immunol. 2013 Mar;28(2-3):120-6.

Gatault P, Jollet I, Paintaud G, Magdelaine C, Bridoux F, Lebranchu Y, Büchler M, Touchard G, Thierry A.

Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch.

Hum Immunol 2013, 74 (12) :1616-1618.

Machet L, Samimi M, Delage M, Paintaud G, Maruani A.

Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.

J Am Acad Dermatol 2013, 69 (4) : 649-650.

Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M.

Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.

Clin Rheumatol. 2013 May;32(5):695-700.

Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

mAbs 2013, 5 (4) : 614-619.


Crocchiolo R, Ciccolini J, El-Cheikh J, Fürst S, Castagna L, Granata A, Oudin C, Harbi S, Devillier R, Legall S, Ternant D, Paintaud G, Lacarelle B, Blaise D.

Successful treatment of a post-transplant ebv-related meningoencephalitis by intravenous rituximab monotherapy (letter). 

Leuk Lymphoma 2012, 53 (10) : 2063-2065. 

Dupuis-Girod, I. Ginon I, Guillot E, Marion D, Decullier E, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie P, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Saurin JC, Faure F. 

Efficacy and safety of Bevacizumab in the treatment of Hemorrhagic Hereditary Telangiectasia (HHT) associated with severe hepatic vascular malformations. A Phase II study. 

JAMA 2012, 307 (9) : 948-955. 

Louis E, Mary JY, Vernier–Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M. 

Maintenance of Remission Among Patients With Crohn’s Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. 

Gastroenterology 2012, 142 (1) : 63-70. 

Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P. 

Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? (review) 

Joint Bone Spine 2012, 79 (2) : 109-112. 

Paintaud G, Diviné M, Lechat P and participants of Round Table N°5 of Giens XXVII.

Monoclonal antibodies for therapeutic use: specific characteristics of clinical development, evaluation by the agencies, and long-term monitoring of safety (review). 

Therapie 2012, 67 (4) : 329-337. 

Samson G, Calera AG, Dupuis-Girod S, Faure F, Decullier E, Paintaud G, Vignault C, Scoazec JY, Pivot C, Plauchu H, Pirot F. 

Ex vivo study of bevacizumab transport through porcine nasal mucosa. 

Eur J Pharm Biopharm 2012, 80 (2) : 465-469. 

Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. 

Br J Clin Pharmacol 2012, 73 (1) : 55-65. 

Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G

Model-based design of rituximab dosing optimization in follicular non-Hodgkin lymphoma. 

Br J Clin Pharmacol 2012,73 (4) : 597-605. 


Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

Clin Cancer Res 2011, 17 (19) : 6329-6337.

Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P.

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. 

Arthritis Res Ther 2011, 13 (3) : R105. 

Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy‑Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc’h N. 

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. 

Pharm Res 2011, 28 (9) : 2147-2156. 

Méric JC, Mulleman D, Ducourau E, Lauféron F, Chu Miow Lin D, Watier H, Goupille P, Paintaud G

Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. 

Ther Drug Monit 2011, 33 (4) : 411-416. 

Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P. 

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. 

Arthritis Res Ther 2011, 13 (3) : R82. 


Chu Miow Lin D, Mulleman D, Azzopardi N, Griffoul-Espitalier I, Valat JP, Paintaud G, Goupille P. 

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. 

Scand J Rheumatol 2010, 39 : 97-98. 

Magdelaine-Beuzelin C, Pinault C, Paintaud G, Watier H. 

Therapeutic antibodies in ophthalmology: old is new again. (review). 

mAbs 2010, 2 : 176-180. 

Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P. 

Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. 

Ther Drug Monit 2010, 32 (2) : 232-236. 

Rosen A, Thimon S, Ternant D, Machet MC, Paintaud G, Machet L.

Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face (letter). 

Br J Dermatol 2010, 163 (1) : 225-227. 

Ternant D, Cézé N, Lecomte T, Degenne D, Duveau AC, Watier H, Dorval E, Paintaud G

An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. 

Ther Drug Monit 2010, 32 (5) : 647-652. 


Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, Watier H, Lecomte T, Paintaud G

An Enzyme-linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. 

Ther Drug Monit 2009, 31 (5) : 597-601. 

Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, Le Pape A, Bardos P, Paintaud G, Cartron G. 

Tumor burden influences exposure and response to rituximab: pharmacokinetic - pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. 

Blood 2009, 113 (16) : 3765-3772. 

Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. 

Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. 

Gastroenterology 2009, 137 (5) : 1628-1640. 

Mulleman D, Méric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P. 

Infliximab concentration monitoring improves the control of disease activity in Rheumatoid arthritis. 

Arthritis Res Ther 2009, 11 (6) : R178. 

Paintaud G, Lejarre F, Ternant D, Goupille P, Watier H. 

Les anticorps monoclonaux : une avancée thérapeutique récente et majeure. 

Therapie 2009, 64 (1) : 1-7. 

Paintaud G

Pharmacocinétique des anticorps monoclonaux. 

Med Sci (Paris) 2009, 25 (12) : 1057-1062. 

Ternant D, Henin E, Cartron G, Tod M, Paintaud G, Girard P. 

Development of a drug - disease simulation model for rituximab in follicular non-Hodgkin lymphoma. 

Br J Clin Pharmacol 2009, 68 (4) : 561-573. 


Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G. 

Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. 

Cancer Res 2008, 68(4):976-80. 

Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. 

J Clin Oncol 2008, 26(33):5489-91; author reply 5491-2. 

Marotte H, Paintaud G, Watier H, Miossec P. 

Rituximab-related late-onset neutropenia in a severe rheumatoid arthritis patient. 

Ann Rheum Dis 2008, 67 : 893-894. 

Ternant D, Büchler M, Beneton M, Alvan G, Ohresser M, Touchard G, Hurault de Ligny B, Toupance O, Watier H, Lebranchu Y, Paintaud G

Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgRIIIa genetic polymorphism. 

Br J Clin Pharmacol 2008, 65 (1) : 60-68. 

Ternant D, Aubourg A, Magdelaine Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G

Infliximab Pharmacokinetics in Inflammatory Bowel Disease patients. 

Ther Drug Monit 2008, 30 (4) : 523-529. 

Thariat J, Azzopardi N, Peyrade F, Launay-Vacher V, Santini J, Lecomte T, Etienne-Grimaldi MC, Paintaud G, Milano G. 

Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. 

J Clin Oncol 2008, 26 (25) : 4223-4225. 

Van Assche GA, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. 

Withdrawal of concomitant immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. 

Gastroenterology 2008, 134 (7) : 1861-1868. 


Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, Le Guellec C. 

Evaluation of a peptide ELISA for the detection of rituximab in serum. 

J Immunol Methods 2007, 325 (1-2) : 127-139. 

Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. 

Pharmacokinetics of rituximab and its clinical use: Thought for the best use? (review). 

Crit Rev Oncol Hematol 2007, 62 (1) : 43-52. 

Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. 

Pharmacokinetics of bevacizumab in hemodialysis (letter). 

Nephrol Dial Transplant 2007, 22 (3) : 975. 

Goupille P, Mulleman D, Paintaud G, Watier H, Valat JP. 

Can sciatica induced by disc herniation be treated by tumor necrosis factor-a blockade? (review). 

Arthritis Rheum 2007, 56 (12) : 3887-3895. 

Paintaud G, Tonelli D, Postaire E. 

Biotherapies: Are they just like any other drugs? (review). 

Therapie 2007, 62 (3) : 235-239. 


Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E.

No association between C-reactive protein gene polymorphisms and decrease of C reactive protein serum concentration after infliximab treatment in Crohn’s disease. 

Pharmacogenetics Pharmacogenomics 2006, 16 : 37–42. 

Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. 

Ther Drug Monit 2006, 28 : 169-174. 


Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L. 

Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in CBCL. 

Br J Dermatol 2005, 152 : 541–544. 

Ternant D, Ohresser M, Thomas C, Cartron G, Watier H, Paintaud G

Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies (letter). 

Blood 2005, 106 (4) : 1503-1504. 

Ternant D, Paintaud G

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins (review). 

Expert Opin Biol Ther 2005, 5 (Suppl. 1) : S37-S47. 


Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H. 

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. 

Aliment Pharmacol Ther 2004, 19 : 511-519. 

Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. 

Rituximab-dependent cytotoxicity by Natural Killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. 

Cancer Res 2004, 64 : 4664-4669.